Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Feb 27, 2024 5:33pm
152 Views
Post# 35902563

RE:RE:RE:Dilution...

RE:RE:RE:Dilution...All of your math is based on conjecture.
the only  time dillution matters is if/ when they get bought out.
A few years ago the math was about $16/billion.
now the math is about $13.6/ billion..
Other than that? They issued millions of shares well under $1. All over the spectrum.over the years.
question being, if they get bought out, could they overall market cap justify the additional shares.
contrary to your statement. The $$ enabled them to move forward with Bracelt, Goblet & other trials that have now placed them into not one but Two phase 3 ready positions.
Had they not raised the $$, The doors would be closed & value would be near zero.
again, come up with a better option? Easy to throw stones.
FYI , for the math illiterate crowd. Take 1000 &  divide by the number of shares.( in millions) 
cancelling out a bunch of zeros, present status 1000/ 73= $13.69 usd/ ps.
I intentionally use the word about. As the number of shares changes & a matter of when we use the point of reference.
There is a lot of unrealized shaeholder aka trading SP value.
why?
biggest reason is uncertainty.
people blame management for the paid advertising, then out iof the other side of their mouths claim management is not updating the market.
They have to counter the never ending plethora of paid bashers on here some how.
BTW, the only way the uoside can be realized is a partership or buyout.
Everone knows that.


<< Previous
Bullboard Posts
Next >>